Introducing

A resource designed to support patients receiving IDACIO (adalimumab) and their healthcare professionals

Help us direct you to the right information by selecting one of the following options. You will need to register to access the full content. Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard (for UK residents) or see http://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects (for residents of the Republic of Ireland). By reporting side effects, you can help provide more information on the safety of this medicine.